Acurx Pharmaceuticals (ACXP) News Today $0.82 +0.07 (+8.77%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Optimistic Buy Rating for Acurx Pharmaceuticals Driven by Promising Ibezapolstat Progress and Strategic Financial PlanningDecember 12, 2024 | markets.businessinsider.comAcurx Pharmaceuticals (NASDAQ:ACXP) Earns "Buy" Rating from HC WainwrightDecember 12, 2024 | americanbankingnews.comAcurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA CommunicationsDecember 9, 2024 | prnewswire.comAcurx Pharmaceuticals (NASDAQ:ACXP) Stock, Insider Trading ActivityNovember 22, 2024 | benzinga.comAcurx Pharmaceuticals Shares Slide 17% After Disclosing Bitcoin InvestmentNovember 20, 2024 | marketwatch.comAcurx board approves Bitcoin as treasury reserve assetNovember 20, 2024 | markets.businessinsider.comAcurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy's playbookNovember 20, 2024 | cnbc.comAcurx Pharmaceuticals, Inc.: Acurx Board of Directors Approves Bitcoin as Treasury Reserve AssetNovember 20, 2024 | finanznachrichten.deAcurx Board of Directors Approves Bitcoin as Treasury Reserve AssetNovember 20, 2024 | prnewswire.comAcurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data UpdateNovember 18, 2024 | prnewswire.comPromising Prospects for Acurx Pharmaceuticals: Buy Rating Backed by Ibezapolstat’s Efficacy and Strategic PositioningNovember 15, 2024 | markets.businessinsider.comAcurx Pharmaceuticals Inc (ACXP) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...November 14, 2024 | finance.yahoo.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | msn.comAcurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comAcurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business UpdateNovember 13, 2024 | prnewswire.comAcurx reports positive Phase 2 results for CDI treatment ibezapolstatOctober 24, 2024 | uk.investing.comAcurx’s ibezapostat shows favorable effect in Phase 2b CDI trialOctober 22, 2024 | markets.businessinsider.comAcurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific ConferenceOctober 21, 2024 | prnewswire.comAcurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor EngagementOctober 17, 2024 | prnewswire.comAcurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024October 16, 2024 | prnewswire.comAcurx Pharmaceuticals (NASDAQ:ACXP) Stock Quotes, Forecast and News SummaryOctober 13, 2024 | benzinga.comAcurx reports ibezapolstat's positive microbiome effects and Anthrax activitySeptember 29, 2024 | uk.investing.comAcurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 AnaloguesSeptember 26, 2024 | prnewswire.comAcurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile SymposiumSeptember 24, 2024 | prnewswire.comACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment ConferenceAugust 26, 2024 | prnewswire.comWe're A Little Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn RateAugust 25, 2024 | uk.finance.yahoo.comAcurx Pharmaceuticals LLC (ACXP)August 15, 2024 | investing.comIbezapolstat’s Strategic Advancements and Market Potential Bolster Buy Rating for Acurx PharmaceuticalsAugust 10, 2024 | markets.businessinsider.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q2 2024 Earnings Call TranscriptAugust 10, 2024 | insidermonkey.comAcurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business UpdateAugust 9, 2024 | prnewswire.comUSPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut MicrobiomeJuly 17, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business UpdateJuly 16, 2024 | prnewswire.comAcurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific ConferenceJuly 15, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Call TranscriptMay 17, 2024 | seekingalpha.comBuy Rating Affirmed for Acurx Pharmaceuticals Amid Promising CDI Drug Candidate Progress and Solid FinancialsMay 17, 2024 | markets.businessinsider.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2024 Earnings Call TranscriptMay 16, 2024 | insidermonkey.comAcurx Pharmaceuticals Inc (ACXP) Q1 2024 Earnings Call Transcript Highlights: Key Financial and ...May 16, 2024 | finance.yahoo.comQ1 2024 Acurx Pharmaceuticals Inc Earnings CallMay 16, 2024 | finance.yahoo.comAcurx Pharmaceuticals Inc Ordinary SharesMay 15, 2024 | morningstar.comAcurx Pharmaceuticals GAAP EPS of -$0.28 misses by $0.04May 15, 2024 | msn.comAcurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile InfectionMay 15, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business UpdateMay 15, 2024 | prnewswire.comAcurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific ConferenceMay 2, 2024 | finance.yahoo.comAcurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific ConferenceMay 2, 2024 | prnewswire.comAcurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific ConferenceApril 25, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business UpdateApril 23, 2024 | prnewswire.comAcurx Pharmaceuticals Rings the Closing BellApril 17, 2024 | nasdaq.comAcurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | seekingalpha.comAcurx Pharmaceuticals: Strong Buy on Ibezapolstat’s Promising Phase 3 Trials and Strategic PartnershipsMarch 19, 2024 | markets.businessinsider.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | finance.yahoo.com Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address Combine the QQQ, IWM and SPY in one trade (Ad)If you’ve been investing in the major indexes for the last 20 years, you may need a new strategy. Because the Dow Jones has returned just 349%... The Russell 2000 has returned just 397%... And the S&P 500 has returned just 450%. And although I can’t guarantee results or against losses… I want to tell you about my “2-Click Trade” that has encapsulated more than the return of ALL THREE OF THOSE INDEXES COMBINED… Plus, it targets multiple overnight payouts in a month with 84.3% accuracy! While I cannot promise future returns or against losses… You can find out about this “2-Click Trade” here. ACXP Media Mentions By Week ACXP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACXP News Sentiment▼0.000.61▲Average Medical News Sentiment ACXP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACXP Articles This Week▼01▲ACXP Articles Average Week Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Immuneering News Shattuck Labs News Iterum Therapeutics News AlloVir News IO Biotech News Celularity News Omega Therapeutics News vTv Therapeutics News Aileron Therapeutics News CASI Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACXP) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
